These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35693456)

  • 1. Selectivity and Maximum Response of Vibegron and Mirabegron for β
    Brucker BM; King J; Mudd PN; McHale K
    Curr Ther Res Clin Exp; 2022; 96():100674. PubMed ID: 35693456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density.
    Yamamoto S; Kusabuka H; Matsuzawa A; Maruyama I; Yamazaki T
    PLoS One; 2023; 18(9):e0290685. PubMed ID: 37656760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
    Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
    Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of real-world adherence and persistence patterns with vibegron, mirabegron, and anticholinergics in patients with overactive bladder: A retrospective claims study.
    Chastek B; Carrera A; Landis C; Snyder D; Abedinzadeh L; Bancroft T; Nesheim J; Kennelly M; Staskin D
    Neurourol Urodyn; 2024 Sep; 43(7):1504-1513. PubMed ID: 38720543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis.
    Kennelly M; Wielage R; Shortino D; Thomas E; Mudd PN
    Drugs Context; 2022; 11():. PubMed ID: 36303599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
    Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
    BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of β
    Krhut J; Skugarevská B; Míka D; Lund L; Zvara P
    Res Rep Urol; 2022; 14():167-175. PubMed ID: 35502186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vibegron inhibits enhanced spontaneous contractions induced by anoxia/reoxygenation in isolated whole bladder from rats.
    Ikeda M; Nakada A; Abukawa H; Yamazaki T; Maruyama I
    Eur J Pharmacol; 2022 Jul; 926():175017. PubMed ID: 35588870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirabegron, a β
    Mendes-Silvério CB; Alexandre EM; Lescano CH; Antunes E; Mónica FZ
    Eur J Pharmacol; 2018 Jun; 829():79-84. PubMed ID: 29654782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term safety and efficacy of the novel β
    Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
    Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacology of β-3 adrenergic receptor agonists for cardiovascular diseases.
    Balligand JL; Michel LYM
    Expert Rev Clin Pharmacol; 2023; 16(11):1073-1084. PubMed ID: 37728503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells.
    Carpéné C; Galitzky J; Fontana E; Atgié C; Lafontan M; Berlan M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):310-21. PubMed ID: 10344530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of mexiletine as an antagonist of beta-adrenoceptor in Chinese hamster ovary cells expressing cloned human beta-adrenoceptors.
    Sakamoto K; Karikomi Y; Kubota Y; Nakahara T; Ishii K
    Biochem Pharmacol; 2004 Mar; 67(5):815-22. PubMed ID: 15104234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.
    Alexandre EC; Kiguti LR; Calmasini FB; Silva FH; da Silva KP; Ferreira R; Ribeiro CA; Mónica FZ; Pupo AS; Antunes E
    Br J Pharmacol; 2016 Feb; 173(3):415-28. PubMed ID: 26493129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The β
    Mo W; Michel MC; Lee XW; Kaumann AJ; Molenaar P
    Br J Pharmacol; 2017 Aug; 174(16):2706-2715. PubMed ID: 28574581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive effects of intravenous and intravesical application of vibegron, a β
    Furuta A; Suzuki Y; Igarashi T; Koike Y; Kimura T; Egawa S; Yoshimura N
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2073-2080. PubMed ID: 32556396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys.
    Hatanaka T; Ukai M; Watanabe M; Someya A; Ohtake A; Suzuki M; Ueshima K; Sato S; Masuda N
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Nov; 386(11):1001-8. PubMed ID: 23832377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vibegron, a Novel Potent and Selective β
    Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
    Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vibegron in patients with overactive bladder: Multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01.
    Tachikawa K; Kyoda Y; Fukuta F; Kobayashi K; Masumori N
    Low Urin Tract Symptoms; 2022 Mar; 14(2):109-116. PubMed ID: 34713579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.